Passage Bio Ownership
| PASG Stock | USD 0.58 0.03 4.92% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 61.7 M | Current Value 61.8 M | Avarage Shares Outstanding 46.9 M | Quarterly Volatility 13.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Passage |
Passage Stock Ownership Analysis
About 60.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Passage Bio recorded a loss per share of 1.17. The entity had not issued any dividends in recent years. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To find out more about Passage Bio contact William MD at 267 866 0311 or learn more at https://www.passagebio.com.Besides selling stocks to institutional investors, Passage Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Passage Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Passage Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Passage Bio Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Passage Bio are currently held by insiders. Unlike Passage Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Passage Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Passage Bio's insider trades
Passage Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Passage Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Passage Bio backward and forwards among themselves. Passage Bio's institutional investor refers to the entity that pools money to purchase Passage Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fiduciary Trust Co | 2024-09-30 | 215 K | Millennium Management Llc | 2024-09-30 | 163.9 K | Rbf Llc | 2024-09-30 | 142.8 K | State Street Corp | 2024-09-30 | 123.9 K | Two Sigma Investments Llc | 2024-09-30 | 98 K | Shay Capital Llc | 2024-09-30 | 92.3 K | Landscape Capital Management,llc | 2024-09-30 | 53.9 K | Northern Trust Corp | 2024-09-30 | 40.3 K | Engineers Gate Manager Lp | 2024-09-30 | 34.8 K | Orbimed Advisors, Llc | 2024-09-30 | 9.8 M | Vestal Point Capital Lp | 2024-09-30 | 6.1 M |
Passage Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Passage Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Passage Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Passage Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Passage Bio Outstanding Bonds
Passage Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Passage Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Passage bonds can be classified according to their maturity, which is the date when Passage Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.